Filament is an exclusively-natural psychedelic drug discovery and extraction company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. Filament believes measurable and efficacious medicines will be a catalyst to addressing many of the world’s mental health problems and that natural psychedelics provide an optimal option for widespread adoption of these substances. Filament engages in natural extraction technology and commercialization, utilizing its intellectual property portfolio, in-house good manufacturing practices and a Health Canada psilocybin Dealer’s License. Filament is headquartered in Vancouver, British Columbia.
Stock Performance
Filament Health News 82 articles
- Germany launches EU's first psilocybin compassionate-use program using Filament Health's PEX010
- Filament Health Announces First Quarter 2025 Financial Results and Operational Highlights
- Filament Health Announces FDA Authorization Of Phase 2 Clinical Trial Studying PEX010, The Company’s Botanical Psilocybin Drug Candidate, In Opioid Use Disorder
- Filament Health Reports Q4 and Year End 2024 Financial Results and Operational Highlights
- Filament Health Announces Positive Data From Phase 2 Study of PEX010 in Patients With Alcohol Use Disorder
- Filament Health Announces Shipment Of Botanical Psilocybin To The University of Wisconsin-Madison
- Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum
- Jaguar Health Announces Import of Coca Leaf from Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications
- Filament Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences
- Filament Health Announces Third Quarter 2024 Financial Results and Operational Highlights
- Filament Health Announces Issuance of Common Shares to Negev Capital Investments Limited Pursuant to Advisory Agreement
- Filament Health Announces Second Quarter 2024 Financial Results and Operational Highlights
- Filament Health Announces Major Intellectual Property Expansion
- Filament Health Announces Closing of Warrant Exercise, Note Conversion and Concurrent Private Placement of Common Shares
- Filament Health Announces Warrant Exercise and Note Conversion by Negev Capital and Concurrent Private Placement of Common Shares to Benjamin Lightburn, Chief Executive Officer
- Filament Health Announces Authorization of Phase 2 Clinical Trial for PEX010 in the Treatment of Methamphetamine Use Disorder
- Filament Health Announces First Quarter 2024 Financial Results and Operational Highlights
- Filament Health Nets $2.1M in Revenue in 2023
- Filament Health To Discuss Its Drug Development Platform in Fireside Chat With Water Tower Research on April 4, 2024 at 12PM ET
- Filament Health Announces Appointment of Michael Messinger To Its Board of Directors
- Filament Health Announces Shipments of Botanical Psilocybin to Four Countries for Clinical Investigation
- Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions
- Filament Health Announces FDA Opening of Investigational New Drug Application for Substance Use Disorders
- Filament Health Completes the First Export of Botanical Psilocybin to Australia
- Filament Health Announces Change To Board of Directors
- Filament Health Announces Termination of Proposed Business Combination With Jupiter Acquisition Corporation
- Filament Health Announces Termination of Shareholder Meeting and Engagement of Donohoe Advisory for Compliance Expertise
- Filament Health Announces Adjournment of Special Meeting
- Filament Health Announces signing of definitive agreement for convertible note financing, closing of $900,000 non-brokered private placement financing
- Filament Health Signs Non-Binding Term Sheet for Convertible Note in Connection with Planned Business Combination
- PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules
- Filament Health Announces Third Quarter 2023 Financial Results and Operational Highlights
- Filament Health Announces Health Canada Authorization for Phase 2 Clinical Trial Studying Botanical Psilocybin for Opioid Use Disorder
- Jupiter Acquisition Files Investor Presentation on Filament Health Deal
- Filament Health Corp. Announces Non-Brokered Private Placement Unit Offering Led By Negev Capital
- Filament Health and Jaguar Health Joint Venture Magdalena Biosciences Completes Import of Coca Leaf From Peru
- Filament Health Enters Licensing Agreement With Reset Pharma
- Filament Health and Nasdq-Listed SPAC Jupiter Acquisition Corp. Announce Filing of SEC Registration Statement
- Filament Health Announces FDA Approval of Two Clinical Trials Studying Its Botanical Psilocybin Drug Candidate PEX010
- Filament Health Announces Upsizing and Closing of $2,500,000 Non-Brokered Private Placement Financing
Showing the 40 most recent of 82 articles.